PRELUDE THERAPEUTICS
Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival, and resistance. The company's offerings include developing a pipeline of novel, orally bioavailable, small-molecule therapies to target critical intervention points in pathways of resistance to overcome treatment failure in cancer, enabling healthcare providers to discover potential treatments that offer hope to people with cancer. Prelude Therapeutics was founded in 2016 by Krishna Vaddi and is based in Wilmington, Delaware.
PRELUDE THERAPEUTICS
Industry:
Biopharma Biotechnology Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Wilmington, Delaware, United States
Country:
United States
Website Url:
http://www.preludetx.com
Total Employee:
101+
Status:
Active
Contact:
(302)467-1280
Email Addresses:
[email protected]
Total Funding:
147 M USD
Technology used in webpage:
Google Maps ReCAPTCHA V2 CPanel Smart App Banner Google No Translate Akamai Hosted Comcast GlobalSign Ninja Forms AlphaSSL
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Longevity Biotech
Longevity Biotech develops a new class of therapeutics via artificial protein technology that focuses on pharmaceutical preparation.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Official Site Inspections
http://www.preludetx.com Semrush global rank: 1.98 M Semrush visits lastest month: 10.69 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Prelude Therapeutics"
Prelude Therapeutics - Crunchbase Company Profile
Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival, and resistance. The company's offerings include developing a pipeline of novel, orally bioavailable, small-molecule …See details»
Leadership - Prelude Therapeutics
Dr. Huang was appointed President and Chief Medical Officer of Prelude in April 2022. Prior to joining Prelude, she served as Chief Medical Officer of Hematology at BeiGene, Ltd., where …See details»
Board of Directors - Prelude Therapeutics
While at Genentech, he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. Mr. Babler previously served at Eli Lilly and Company in positions focused on …See details»
Working At Prelude Therapeutics: Company Overview and Culture
May 18, 2020 preludetx.com. Organization Type. Public. Social Media. Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival and …See details»
SEC Filing - Prelude Therapeutics
The costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current or future product candidates; the …See details»
Prelude Therapeutics Company Overview, Contact Details ... - LeadIQ
[email protected]: 1%. See more formats. Frequently Asked Questions Where is Prelude Therapeutics 's headquarters located? Prelude Therapeutics 's main headquarters is located …See details»
Prelude Therapeutics - Overview, News & Similar companies
May 26, 2024 www.preludetx.com. Revenue $142.3 Million. Stock Symbol PRLD. Industry Pharmaceuticals Healthcare . Most Recent Scoops. Jul 26 2024. Project. May 27 2024. Event. …See details»
Corporate Presentation - investors.preludetx.com
Sep 13, 2024 5 Prelude’s Evolution Strategic Priorities • Continue to build SMARCA leadership • Generate proof-of-concept data • Prepare for global registrational trials • Advance SMARCA …See details»
Martin Babler - Prelude Therapeutics
Martin Babler joined the Board of Directors in July 2021. Mr. Babler currently serves as President, Chief Executive Officer and Chairman of the Board of Directors of Alumis. Prior thereto he …See details»
Prelude Therapeutics - Craft
Prelude Therapeutics has 5 employees across 2 locations and $122 m in total funding,. See insights on Prelude Therapeutics including office locations, competitors, revenue, financials, …See details»
THIS POLICY WAS APPROVED BY THE BOARD ON SEPTEMBER 2, …
Prelude Therapeutics Incorporated 3 Code of Business Conduct and Ethics • Board Service: Serving as a board member or advisor for an outside company or organization • Investments: …See details»
Overview - Prelude Therapeutics
Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines. …See details»
Corporate Presentation - investors.preludetx.com
Forward Looking Statements This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of …See details»
Madhu Pudipeddi, Ph.D. - Prelude Therapeutics
Madhu Pudipeddi, Ph.D. is Senior Vice President, Technical Operations at Prelude Therapeutics. Prior to joining Prelude, he was Executive Director at Novartis Pharmaceuticals, where he had …See details»
P re l u d e T h e r ap e u ti c s I n c or p or ate d
Includes 99,144 shares of Common Stock of the Issuer underlying 99,144 Stock Options and 5,188 shares of Common Stock directly held by the Adviser from Exercised Stock Options (as …See details»
Jane Huang, M.D., Joins Prelude Therapeutics as President
WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that Jane …See details»
Prelude Therapeutics Announces Appointment of Martin Babler to …
Mr. Babler previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development. He presently serves on the Board …See details»
Careers - Prelude Therapeutics
Our Culture At Prelude Therapeutics we believe great people make great science. Our strength lies in the talented individuals who work here, and they truly hold the key to our success. …See details»
Release Details - Prelude Therapeutics
Jun 12, 2019 Prelude is focused on the discovery and development of small molecule agents targeting novel molecular mechanisms that drive cancer cell growth, survival and resistance to …See details»